Screener
Capricor Therapeutics CAPR Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Capricor Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
FAQ
- What is Capricor Therapeutics's debt-to-equity?
- Capricor Therapeutics (CAPR) reported debt-to-equity of 0.1× in Q1 2026.
- How has Capricor Therapeutics's debt-to-equity changed year-over-year?
- Capricor Therapeutics's debt-to-equity increased by 440.8% year-over-year, from 0× to 0.1×.
- What is the long-term trend for Capricor Therapeutics's debt-to-equity?
- Over 5 years (2020 to 2025), Capricor Therapeutics's debt-to-equity has grown at a 80.2% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Capricor Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude